Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
CTXR closed down 4.12 percent on Friday, October 19, 2018, on 22 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|See historical CTXR trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 19||Narrow Range Bar||Range Contraction||0.00%|
|Oct 19||NR7||Range Contraction||0.00%|
|Oct 19||Strong but Oversold||Other||0.00%|
|Oct 19||Strong, Oversold and Reversal Signs||Reversal||0.00%|
|Oct 19||Oversold Stochastic||Weakness||0.00%|
|Oct 18||20 DMA Resistance||Bearish||-4.12%|
|Oct 18||Stochastic Buy Signal||Bullish||-4.12%|
|Oct 18||Strong but Oversold||Other||-4.12%|
|Oct 18||Oversold Stochastic||Weakness||-4.12%|
|Oct 17||Strong but Oversold||Other||0.62%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 1 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CTXR news...
|52 Week High||5.49|
|52 Week Low||1.12|
|200-Day Moving Average||2.6432|
|50-Day Moving Average||1.5732|
|20-Day Moving Average||1.724|
|10-Day Moving Average||1.679|
|Average True Range||0.1699|
|Chandelier Exit (Long, 3 ATRs )||2.0103|
|Chandelier Exit (Short, 3 ATRs )||1.9597|
|Upper Bollinger Band||1.8721|
|Lower Bollinger Band||1.5759|
|Percent B (%b)||0.18|
|MACD Signal Line||0.0159|
|Market Cap||13.45 Million|
|Num Shares||8.25 Million|
|Price-to-Earnings (P/E) Ratio||-0.82|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||1.74|
|Resistance 3 (R3)||1.73||1.70||1.72|
|Resistance 2 (R2)||1.70||1.67||1.70||1.71|
|Resistance 1 (R1)||1.66||1.65||1.67||1.67||1.71|
|Support 1 (S1)||1.59||1.60||1.60||1.60||1.55|
|Support 2 (S2)||1.56||1.58||1.56||1.55|
|Support 3 (S3)||1.52||1.56||1.54|
|Support 4 (S4)||1.53|